
	Versartis, Inc., a biotechnology company, develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders by using XTEN, a hydrophilic amino acid sequence that prolongs the half-life of proteins and peptides. Its products include VRS-859 for the treatment of type 2 diabetes; VRS-826 for the treatment of type 2 diabetes and rheumatoid arthritis; VRS-808 for prevention of nocturnal hypoglycemia in type 1 diabetics (primarily children); and VRS-317 for growth hormone deficiency in children and adults. Versartis, Inc. was founded in 2008 and is based in Redwood City, California.
